ARTICLE | Clinical News

Aduro bounces back after disclosing infection

November 26, 2015 12:04 AM UTC

Aduro Biotech Inc. (NASDAQ:ADRO) gained $4.42 (16%) to $31.47 Wednesday after it allayed investor concerns about a listeriosis infection in one patient receiving CRS-207 and GVAX Pancreas cancer vaccine in a Phase IIa trial. Aduro said all of its clinical trials will continue as planned.

The move nearly completed a round-trip in trading for Aduro, which fell 16% Tuesday after it disclosed in a regulatory filing Monday that a pancreatic cancer patient treated with CRS-207 and GVAX Pancreas developed listeriosis. ...